Trial · NCT07881601
Effects of Ubiquinol and Ubiquinone on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol
NCT07881601, Not applicable, Enrolling by invitation, SF Research Institute, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Ubiquinol and Ubiquinone on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol. Trials, record NCT07881601. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07881601
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Ubiquinol and Ubiquinone on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol
- NCT number
- NCT07881601
- Status
- Enrolling by invitation
- Phases
- Not applicable
- Enrollment
- 120 participants, estimated
- Lead sponsor
- SF Research Institute, Inc.
- Conditions
- Borderline High LDL-cholesterol
- Interventions
- Ubiquinol, Ubiquinone, Placebo
- First posted
- 2026-10-19
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Flow-Mediated Dilation (FMD) | Baseline, Week 4, Week 8 | Change in Flow-Mediated Dilation (FMD), a measure of vascular endothelial function. |
| Secondary | Change in Total Plasma CoQ10 Concentration | Baseline, Week 4, Week 8 | Change from baseline in the absolute concentration of total coenzyme Q10 (CoQ10) in plasma, measured in μg/mL. |
| Secondary | Change in Plasma Ubiquinol Concentration | Baseline, Week 4, Week 8 | Change from baseline in the absolute concentration of reduced coenzyme Q10 (ubiquinol) in plasma, measured in μg/mL. |
| Secondary | Change in Plasma Ubiquinone Concentration | Baseline, Week 4, Week 8 | Change from baseline in the absolute concentration of oxidized coenzyme Q10 (ubiquinone) in plasma, measured in μg/mL. |
| Secondary | Change in Ratio of Reduced to Total CoQ10 | Baseline, Week 4, Week 8 | Change from baseline in the ratio of reduced CoQ10 (ubiquinol) to total CoQ10 in plasma. |
| Secondary | Change in Plasma Nitric Oxide (NO) | Baseline, Week 4, Week 8 | Change from baseline in plasma nitric oxide (NO), assessed by nitrite/nitrate quantification. |
| Secondary | Change in LDL Oxidation Susceptibility | Baseline, Week 4, Week 8 | Change from baseline in LDL oxidation susceptibility, measured as lag time using a copper-induced assay. |
| Secondary | Change in Malondialdehyde (MDA) Levels | Baseline, Week 4, Week 8 | Change from baseline in serum levels of malondialdehyde (MDA), an oxidative stress marker. |
| Secondary | Change in Oxidized LDL (oxLDL) Levels | Baseline, Week 4, Week 8 | Change from baseline in serum levels of oxidized low-density lipoprotein (oxLDL), an oxidative stress marker. |
| Secondary | Change in Total Antioxidant Capacity (TAC) | Baseline, Week 4, Week 8 | Change from baseline in serum total antioxidant capacity (TAC). |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07881601
GET https://conductscience.org/api/trials/v1/NCT07881601/registered